Brokerages Set Bruker Corporation (NASDAQ:BRKR) Target Price at $50.54

Bruker Corporation (NASDAQ:BRKR) has received an average recommendation of “Hold” from the fifteen brokerages that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $51.3077.

A number of equities research analysts recently commented on the company. Wolfe Research assumed coverage on Bruker in a research report on Monday, June 1st. They issued a “peer perform” rating for the company. Guggenheim lowered their price target on Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, March 30th. Stifel Nicolaus set a $45.00 price target on Bruker in a research report on Friday, May 8th. Citigroup increased their price target on Bruker from $40.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Finally, The Goldman Sachs Group lowered their price target on Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a research report on Friday, February 13th.

Insider Activity

In other news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at $5,124,875.70. This trade represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 27.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bruker

Several large investors have recently made changes to their positions in the business. NewEdge Advisors LLC increased its position in shares of Bruker by 5,291.2% during the 1st quarter. NewEdge Advisors LLC now owns 1,833 shares of the medical research company’s stock valued at $66,000 after purchasing an additional 1,799 shares during the last quarter. Essential Partners LLC purchased a new stake in shares of Bruker during the 1st quarter valued at $36,000. Groupe la Francaise purchased a new stake in shares of Bruker during the 1st quarter valued at $1,222,000. Liontrust Investment Partners LLP increased its position in shares of Bruker by 113.3% during the 1st quarter. Liontrust Investment Partners LLP now owns 3,844 shares of the medical research company’s stock valued at $139,000 after purchasing an additional 2,042 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Bruker by 2.1% during the 1st quarter. Janus Henderson Group PLC now owns 100,380 shares of the medical research company’s stock valued at $3,625,000 after purchasing an additional 2,090 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Trading Down 4.1%

NASDAQ BRKR opened at $54.92 on Friday. The firm has a market capitalization of $8.36 billion, a P/E ratio of -228.83, a PEG ratio of 1.83 and a beta of 1.31. The business has a fifty day simple moving average of $43.87 and a 200 day simple moving average of $43.73. Bruker has a 12 month low of $28.53 and a 12 month high of $64.54. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The business had revenue of $823.40 million during the quarter, compared to analyst estimates of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.Bruker’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts predict that Bruker will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio (DPR) is currently -83.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.